rezatapopt — NDA/BLA submission
Q1 2027
Recent FDA interaction supports NDA submission strategy for accelerated approval of rezatapopt for platinum-resistant/refractory ovarian cancer, with submission planned in first quarter of 2027Source filing
PMVP biotech catalysts & pipeline
PMV PHARMACEUTICALS INC · Data as of 2026-09-08
Upcoming catalysts
rezatapopt — Conference presentation
Q4 2026
PMV plans to provide an update on all PYNNACLE Phase 2 pivotal trial cohorts at a medical conference in fourth quarter of 2026Source filing